You are here

Rare Disease Areas of Interest

Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Cheladv74 support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Cheladv74 Global Reviewers. A formal notification regarding the status of your application will be sent once a decision is reached. Cheladv74 support will only be extended upon the execution of a research agreement. For any questions, please send an email to [email protected].

Question Pairs: 
Question: 

Endocrine: pegvisomant

Answer: 

Research areas to be considered for funding include:

  • Morbidity and mortality in patients with Acromegaly/GH Excess
  • Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat acromegaly/GH Excess
  • Early diagnosis and treatment of acromegaly/GH Excess; consequences of late diagnosis/treatment initiation
  • Pharmacoeconomics such as but not limited to resource utilization; patient-reported outcomes; treatment patterns
  • Preclinical studies (Material Transfer Agreements with funding request) would be considered in the ISR program
Question: 

Gaucher Disease: taliglucerase

Answer: 

Research areas to be considered for Cheladv74 support include:

Coming Soon!

Question: 

Hemophilia

Answer: 

Research areas to be considered for Cheladv74 support include:

  • Basic Science of Gene Therapy for Hemophilia

    • Basic science, tropism, transduction efficiency & tolerability of Adeno-associated virus
    • AAV antibody Titer assessment, reduction, tolerance
    • Role of immunosuppression in managing transaminitis
  • Patients with MILD Hemophilia A or B

    • Natural history of mild Hemophilia
    • Arthropathy: presence, development, clinical burden & Joint damage in mild Hemophilia
    • Quality of Life/Work analysis and cost of care in mild Hemophilia
    • Development and validation of PRO (Patient Reported Outcomes) instruments in Hemophilia
Question: 

Sickle Cell Disease

Answer: 

Research areas to be considered for Cheladv74 support include:

Coming Soon!

Question: 

TTR Amyloidosis: tafamidis

Answer: 

Research areas to be considered for Cheladv74 support include:

  • Early identification, evaluation, diagnosis, prognosis & treatment
  • Natural history
  • Epidemiology
    • Prevalence of TTR amyloidosis among at-risk populations (e.g. carpal tunnel syndrome, aortic stenosis, hypertrophic cardiomyopathy, lumbar spinal stenosis, hip & knee arthroplasty, atrial fibrillation)
    • Changing epidemiology of cardiac amyloid subtypes (hereditary vs wild-type)
  • Scintigraphy
    • Use of scintigraphy for diagnosis of early disease and/or monitoring disease progression
    • Phenotype and management of patients with Perugini Grade 1 uptake
  • Post organ transplant
    • Use of tafamidis
    • Natural course of disease
  • Study of hereditary ATTR genotypes and phenotypes
    • Non-Val30Met genotypes
    • Val122Ile, Thr60Ala, Val30Met, and others
  • Late-onset disease (onset after 50 years of age)
  • Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)
  • Development of new quality of life measures or patient report outcomes measures in ATTR amyloidosis
  • Use of tafamidis in the clinical setting (i.e. real world evidence)
  • Functional role of TTR in humans or non-human primates

We are not currently accepting proposals focusing on:

  • Head to head studies
  • Any indications outside of TTR amyloidosis
  • Pediatric investigations
  • End stage disease
  • Dose response studies
  • Tafamidis Animal studies (except requests for pure substance only)
Question: 

Transplant: sirolimus

Answer: 

Research areas to be considered for funding include:

  • Preservation of renal function in kidney transplant patients
  • Reduction of post-transplant malignancy
  • Reduction of post-transplant viral infections
  • Improvement in understanding the management of side effects
  • Exploration of the use of sirolimus beyond kidney transplantation

Drug-Supply Only on a case-by-case basis

We are not currenlty accepting proposals focusing on:

  • Protocols which would specify drug supply for topical use
  • Active Drug substance for clinical use
  • Protocols which include product reformation or compounding
  • Protocols which request placebo formations